Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Extensive toxicological and epidemiological research has shown that these carcinogens cause DNA damage, mutational signatures ...

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Taryne A. Imai, MD, found herself at a professional crossroads in 2022. She had been working for seven years as a thoracic surgeon, most recently as Clinical Chief of Thoracic Surgery at Cedars-Sinai ...

Aging is associated with increased risk for nearly every lung disease, including acute conditions like pneumonia and chronic diseases like chronic obstructive pulmonary disease, idiopathic pulmonary ...

Radon, an odorless radioactive gas that seeps from soil into homes, is responsible for an estimated 21,000 lung cancer deaths each year in the United States. That figure, drawn from federal risk ...

Researchers reviewed how somatic mutations accumulate in normal and diseased tissues, showing that natural selection can expand clones that influence disease risk, tissue adaptation, or cellular ...

Lung cancer remains one of the leading causes of cancer deaths around the world. Among the different types of lung cancer, ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.